Persistence and Effectiveness of upadacitinib and TNFi for rheumatoid arthritis using pooled data from Canadian and Swiss registries
Clicks: 3
ID: 318355
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Popular Article
0.6
/100
3 views
2 readers
AI Quality Assessment
Not analyzed
Readership in this journal
PopularRanked #47 of 202 articles by views in Lara D. Veeken
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 202 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Abstract Objectives The ROSA study evaluated real-world persistence and effectiveness of upadacitinib and tumour necrosis factor inhibitors (TNFi) in patients with rheumatoid arthritis (RA), using data from 2 Canadian registries, RHUMADATA and Ontario Best Practices Research Initiative (OBRI), and the Swiss Clinical Quality Management in Rheumatic Diseases (SCQM) registry. Methods This observational study analysed data from 990 patients with RA who initiated upadacitinib or TNFi between 01-Jan-2020 and 30-Jun-2023. Multiple imputation was used for baseline covariates with missing data and results were adjusted for propensity scores derived from pre-specified variables (age, disease duration, prior treatments, comorbidities, etc.). Persistence was assessed using Kaplan-Meier and Cox proportional hazard regression models. Effectiveness was evaluated using observed (non-imputed) disease activity indices over 6 and 12 months. Results Overall, 174, 216, and 600 patients were included from the RHUMADATA, OBRI, SCQM registries, respectively. Patients using upadacitinib had a lower risk of discontinuing treatment than patients using TNFi (hazard-ratio [HR] [95%CI]: 0.602 [0.469, 0.773]) and this was unaffected by previous exposure to advanced treatment. Concomitant use of any csDMARD (HR [95% CI]; upadacitinib: 0.225 [0.107, 0.471]; TNFi: 0.516 [0.303, 0.881]), and methotrexate (upadacitinib: 0.604 [0.390, 0.934]; TNFi: 0.694 [0.522, 0.925]) were associated with improved persistence for both groups. A similar proportion of patients receiving upadacitinib or TNFi achieved Clinical Disease Activity Index low disease activity or remission at 6 months (70.8% vs 61.0%; p = 0.1541) and 12 months (70.5% vs 75.2%; p = 0.4494). Conclusion Canadian and Swiss patients with RA had longer persistence with upadacitinib than TNFi, independent of previous advanced treatments.
| Reference Key |
openalex_W7165654760
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | D. Choquette, Axel Finckh, Andrea Rubbert‐Roth, Louis Coupal, Xiuying Li, Sibel Zehra Aydın, Helene Jonasch, Roger Gaertner, Dalinda Liazoghli, Mohammad Movahedi |
| Journal | Lara D. Veeken |
| Year | 2026 |
| DOI |
10.1093/rheumatology/keag301
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.